论文部分内容阅读
今年4月底,首个全口服直接抗丙肝病毒联合治疗方案——百立泽(盐酸达拉他韦片)和速维普(阿舒瑞韦软胶囊)获国家食品药品监督管理总局批准上市。我国丙肝防治终于进入DAA(直接抗病毒)时代,相比于传统治疗方案,DAA小分子口服药可显著提高治愈率、缩短抗病毒治疗疗程、减少副作用。最为专家和广大患者所关注的还是费用,这是DAA小分子口服药能否真正广泛应用于临床并产生效果的关键。以美国首个批准的
The end of April this year, the first full oral direct combination of anti-hepatitis C treatment programs - one hundred Ze (daltephedrine hydrochloride tablets) and speed Victoria Pu (arsaruwe soft capsules) by the State Food and Drug Administration approved the listing. Our country hepatitis C prevention and control finally entered the DAA (direct antiviral) era, compared to the traditional treatment programs, DAA small molecule oral medication can significantly improve the cure rate, shorten the course of antiviral therapy, reduce side effects. The most experts and the majority of patients are concerned about the cost or not, which is the key DAA small molecule oral drugs can be truly widely used in clinical and produce results. First approved by the United States